Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Sorrento Therpt (SRNE)

4.56   0.23 (5.31%) 01-16 19:20
Open: 4.27 Pre. Close: 4.33
High: 4.58 Low: 4.23
Volume: 5,245,937 Market Cap: 1,397M
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.582 - 4.605 4.605 - 4.628
Low: 4.18 - 4.202 4.202 - 4.224
Close: 4.522 - 4.559 4.559 - 4.597

Technical analysis

as of: 2022-01-15 8:49:56 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 6.51     One year: 7.49
Support: Support1: 4.23    Support2: 3.52
Resistance: Resistance1: 5.58    Resistance2: 6.41
Pivot: 4.72
Moving Average: MA(5): 4.55     MA(20): 5.00
MA(100): 6.55     MA(250): 8.13
MACD: MACD(12,26): -0.38     Signal(9): -0.37
Stochastic oscillator: %K(14,3): 10.07     %D(3): 12.63
RSI: RSI(14): 37.70
52-week: High: 17.25  Low: 4.23  Change(%): -54.3
Average Vol(K): 3-Month: 549152  10-Days: 477297

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
SRNE has closed above bottom band by 36.6%. Bollinger Bands are 20.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 31 Dec 1969


Wed, 31 Dec 1969


Wed, 31 Dec 1969


Wed, 31 Dec 1969


Wed, 31 Dec 1969


Wed, 31 Dec 1969


Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M)
% Held by Insiders
% Held by Institutions
Shares Short (K)
Shares Short P. Month (K)

Stock Financials

EPS
EPS Est This Year -1.070
EPS Est Next Year -0.650
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.) -0.268
Sales Per Share 0.168
EBITDA (p.s.) -0.915
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales 27.08
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.